Instrument Inactif

Autres langues Cascadian Therapeutics Inc (USA)

Actions

US14740B6065

Autres langues

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Cascadian Therapeutics Announces 2018 Outlook and Recent Progress	04/01/18
Cascadian Therapeutics Receives Pediatric Investigation Plan Waiver from the European Medicines Agency	02/01/18
Cascadian Therapeutics Added to the Nasdaq Biotechnology Index	13/12/17
Prolonged Progression-Free Survival Reinforces Tucatinib’s Potential for Patients with Advanced HER2+ Metastatic Breast Cancer	07/12/17
Cascadian Therapeutics Reports Third Quarter 2017 Financial Results	08/11/17
Cascadian Therapeutics to Report Third Quarter 2017 Financial Results on November 8, 2017	01/11/17
Cascadian Therapeutics to Participate in Panel Discussions at Two Conferences in November	24/10/17
Cascadian Therapeutics Announces FDA Orphan Drug Designation Granted to Tucatinib for the Treatment of HER2+ Metastatic Colorectal Cancer	27/09/17
Cascadian Therapeutics to Present at the Cantor Fitzgerald Global Healthcare Conference	20/09/17
Tucatinib Data in Multiple Tumor Types Presented at the European Society for Medical Oncology (ESMO) 2017 Congress	11/09/17
Cascadian Therapeutics Announces Poster Presentations on Tucatinib in Multiple Tumor Types at the European Society for Medical Oncology (ESMO) 2017 Congress	28/08/17
Cascadian Therapeutics Reports Second Quarter 2017 Financial Results	08/08/17
Cascadian Therapeutics to Report Second Quarter 2017 Financial Results on August 8, 2017	01/08/17
Cascadian Therapeutics Announces Positive Regulatory Update for Tucatinib in Europe	11/07/17
Oncothyreon USA : Cascadian Therapeutics' Lead Candidate, Tucatinib, Receives Orphan Drug Designation from FDA for Treatment of Breast Cancer Patients with Brain Metastases	08/06/17
Cascadian Therapeutics’ Lead Candidate, Tucatinib, Receives Orphan Drug Designation from FDA for Treatment of Breast Cancer Patients with Brain Metastases	08/06/17
Cascadian Therapeutics to Present at Jefferies 2017 Healthcare Conference	31/05/17
Cascadian Therapeutics Reports First Quarter 2017 Financial Results Conference Call Scheduled for Today at 8:30 a.m. ET	09/05/17
Cascadian Therapeutics to Report First Quarter 2017 Financial Results on May 9, 2017	01/05/17
Cascadian Therapeutics Highlights Preclinical Program Presentations at the American Association for Cancer Research Annual Meeting 2017	05/04/17

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Cascadian Therapeutics Inc (USA)

Actions

US14740B6065

Autres langues

Filtres